stoxline Quote Chart Rank Option Currency Glossary
  
Femasys Inc. (FEMY)
0.9  -0.01 (-1.1%)    06-17 16:00
Open: 0.9204
High: 0.93
Volume: 131,429
  
Pre. Close: 0.91
Low: 0.9
Market Cap: 26(M)
Technical analysis
2025-06-17 4:43:34 PM
Short term     
Mid term     
Targets 6-month :  1.11 1-year :  1.29
Resists First :  0.95 Second :  1.11
Pivot price 0.87
Supports First :  0.69 Second :  0.57
MAs MA(5) :  0.89 MA(20) :  0.91
MA(100) :  1.22 MA(250) :  1.16
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  53.9 D(3) :  53.1
RSI RSI(14): 43.5
52-week High :  1.79 Low :  0.69
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ FEMY ] has closed below upper band by 40.9%. Bollinger Bands are 10% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.93 - 0.94 0.94 - 0.94
Low: 0.89 - 0.89 0.89 - 0.9
Close: 0.89 - 0.9 0.9 - 0.91
Company Description

Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.

Headline News

Tue, 17 Jun 2025
Femasys (FEMY) Appoints Kelley Nicholas as Chief Commercial Officer | FEMY Stock News - GuruFocus

Tue, 17 Jun 2025
Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth - Stock Titan

Thu, 12 Jun 2025
Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates - MSN

Wed, 11 Jun 2025
Femasys (FEMY): Buy Rating Reiterated by HC Wainwright & Co. | FEMY Stock News - GuruFocus

Wed, 11 Jun 2025
Femasys Announces Partnership with Carolinas Fertility - GlobeNewswire

Fri, 30 May 2025
Femasys Stock Slides After Company Prices Public Offering At Discount: Retail’s Planning To Load Up - MSN

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Instruments & Supplies
Shares Out 0 (M)
Shares Float 27 (M)
Held by Insiders 2.436e+007 (%)
Held by Institutions 10.5 (%)
Shares Short 852 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.947e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -1 %
Return on Assets (ttm) 600.1 %
Return on Equity (ttm) -65.7 %
Qtrly Rev. Growth 1.7e+006 %
Gross Profit (p.s.) 0.03
Sales Per Share 0.05
EBITDA (p.s.) -0.65
Qtrly Earnings Growth -1 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -20 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 15.04
Price to Cash Flow -33.56
Stock Dividends
Dividend 0
Forward Dividend 799300
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android